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Abstract 
Toxic epidermal necrolysis syndrome is a severe exfoliative condition, which may be 
triggered by anticonvulsant medication. We report a case of toxic epidermal necrolysis 
syndrome in a 43-year-old female who was receiving radiotherapy for brain metastases from 
a recurring breast cancer and phenytoin. She had 80% total body surface area involvement 
and recovered successfully with the application of a nanocrystalline silver dressing. 
 
Introduction 
Toxic epidermal necrolysis syndrome (TENS) is a severe desquamative skin 
condition first described by Lyell in 1956 and has a high mortality rate [1, 2]. Usually, 
patients have ≥30% total body surface area (TBSA) involvement of the skin and 
mucosal surfaces with a positive Nikolsky sign of sloughing epidermis upon rubbing the 
skin surface [3]. Although this condition can be triggered by any medication, it has a 
high association with antibiotics, anti-inflammatory agents, and anticonvulsants [4]. 
Patients undergoing radiotherapy for primary brain tumors or metastases are at risk 
for developing TENS if they have been medicated for seizures or prophylaxis with 
phenytoin, phenobarbital, or carbamazepine [4].  
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Case Report 
In 1996, a 43-year-old Hispanic female was diagnosed and treated for breast cancer. After a 
recurrence 11 years later, she underwent a bilateral mastectomy in 2007. In January 2008, she 
complained of a 2-week history of worsening headaches, photophobia, and vertigo. Computed 
tomography and magnetic resonance imaging showed metastases to the occipital and parietal brain 
and spine. On February 3, 2008, she was started on palliative cranial irradiation of 45 Gy delivered in 
22 fractions at 2 Gy/fraction. At that time, she had the following medications: a tapering dose of 
dexamethasone (4 mg 4 times daily), phenytoin (100 mg 3 times daily) for seizure prophylaxis, and 
antacids. Twenty-three days later, she had developed facial swelling and a diffuse maculopapular 
eruption of the head, scalp, and upper body. She was initially diagnosed with cellulitis and treated 
with clindamycin (900 mg i.v. 3 times daily) and levofloxacin (750 mg i.v. daily), along with 
methylprednisolone (125 mg i.v. 4 times daily). Twenty-six days after the start of her radiation 
therapy, she developed intractable vomiting and blisters, requiring admission for further evaluation. 
She had completed 3 weeks of cranial irradiation, receiving 32 Gy of a planned 45-Gy regimen. Despite 
initiation of antibiotics, her facial swelling worsened and blisters progressed to involve her ears. She 
also experienced odynophagia and dysuria. Phenytoin was discontinued 2 days after admission due to 
a suspicion of a possible drug reaction. Intravenous fluconazole (200 mg daily) was given for oral 
candidiasis and enoxaparin for deep-vein thrombosis prophylaxis. On March 5, 2008, she was 
transferred to the burn center for treatment of TENS. The patient had diffuse erythema and bullae 
with sloughing of facial and scalp epidermis, bilateral conjunctivitis, xerostomia, and oral mucosal 
ulceration with sloughing of the hard and soft palate, and dorsal tongue surface. Widespread bullae 
with a positive Nikolsky sign spread laterally with pressure, to the face, chest, breasts, abdomen, back, 
upper extremities, pelvis, perineum, buttocks, and bilateral thighs, involving 80% TBSA (fig. 1). Skin 
biopsy confirmed the diagnosis of TENS. Due to respiratory failure, the patient was intubated on the 
second day of admission and underwent a tracheostomy to maintain patency of her airway. Her 
laboratory values were within the normal range except for the following (normal values are indicated 
in parentheses): hemoglobin 11.7 (11.5–15.5) g/dl, Hct 33% (35.0–45.0), MCV 79.9 (81.1–96.6), white 
blood count 3.2 (4.5–13.0) ×103/mm3 with 84% neutrophils, 12.8% lymphocytes, 1.9% monocytes, 
0.1% eosinophils, 0.3% basophils, platelets 174 (185–395) ×103/mm3, PT 14.5 (11.8–13.8) s, INR 1.19 
(2.0–3.0), PTT 36.3 (25.6–34.4) s, fibrinogen 525 (196–457) mg/dl, D-dimer 4.89 (0.22–0.43), C-
reactive protein 27.01 (0.0–0.50) mg/dl, prealbumin 8 (18–45) mg/dl, BUN 9 (10.0–20.0) mg/dl, 
creatinine 0.4 (0.6–1.4) mg/dl, calcium 7.3 (8.5–10.5) mg/dl, glucose 159 (65–110) mg/dl, 
phosphorus 2.4 (2.5–4.5) mg/dl, GGT 130 (3.0–60) mg/dl, LDH 246 (85–210) mg/dl, and Na 129 
(135–145) mEq/l. 
She became coagulopathic (PT 17.4 s, PTT 38.3 s). Sheet-like sloughing of her skin progressed, 
including the entire back. Her wounds were cleaned and covered with a silver dressing (ActicoatTM; 
Smith and Nephew, St. Petersburg, Fla., USA). Dressing changes occurred every 3–4 days. Bacitracin 
with zinc oxide was used to lubricate the face, scalp, and neck. She received a 5-day course of 
intravenous γ globulin at 5 mg/kg/day. Corticosteroids were continued, and parenteral nutrition was 
initiated. After 2 weeks of electrolyte correction, fluid resuscitation, and topical wound care, she was 
stabilized, extubated, and her skin reaction resolved; the hospitalization lasted 23 days. 
Discussion 
Due to the extensive skin loss, patients with TENS are at risk for hypothermia and 
infection. They require wound care, pain control, nutrition, and supportive care while 
they regenerate their skin surface, which takes anywhere from 2 to 3 weeks, and is best 
provided in a Burn Center [5]. Our patient was treated effectively with a 
nanocrystalline silver antimicrobial dressing (Acticoat). Literature reports have 
indicated that this dressing improves pain control and decreases the risk of infection, 
and the number of dressing changes required for wound coverage until complete 
healing occurs in burn patients [6, 7]. There have also been reports of Acticoat as 
successful wound coverage for patients with TENS [8–10]. Our patient received  
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intravenous γ globulin as a treatment for TENS. The nanocrystalline silver dressing was 
mainly a barrier against infection of the open wounds. It was tolerated by the patient 
and was unlikely to have influenced the course of the primary disease. 
There are two cautions with this patient. Current recommendations are that patients 
undergoing radiation therapy for primary brain tumors or brain metastases should be 
diligently assessed and avoid the most frequent triggers of TENS among the 
anticonvulsant medications: phenytoin, phenobarbitol, and carbamazepine [11]. Among 
the rashes that occur in patients undergoing radiotherapy (although rare), TENS should 
be considered, especially if the erythematous rash extends outside the radiation field. 
Early referral to a Burn Center to curtail the occurrence of a wound or other infection, 
or ichthyma gangrenosum would benefit the patient in recovery and survival from this 
devastating disease. 
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Fig. 1. Complete sloughing of the skin from the torso of the patient with TENS and 80% TBSA 
involvement. 
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